Why Novavax Stock Is Tumbling Today

Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be disappointed in the company's updates for both its experimental NanoFlu, and respiratory syncytial virus (RSV), vaccine candidates yesterday.

Image source: Getty Images.

Instead of the major clinical update some investors were expecting, Novavax simply noted, per its press release, that the ongoing late-stage RSV study in pregnant women remains on track for a mid-2018 interim analysis, and the company is accelerating enrollment to meet this target.

Source: Fool.com